Redhill Biopharma Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on July 1, 2026, reports the rescheduling of Redhill Biopharma Ltd.'s Annual General Meeting of Shareholders. The meeting was originally scheduled for July 28, 2026, and has been moved to August 6, 2026, to allow for the inclusion of an additional proposal regarding the elimination of share par value. The filing incorporates an updated notice and proxy statement.
Key Financial Metrics
The filing text does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity for the current or prior periods. The document references that shareholders will have the opportunity to review financial statements for the fiscal year ended December 31, 2025, at the meeting, but the figures are not included in this report.
Material Changes and Corporate Actions
- Meeting Reschedule: The Annual General Meeting is now set for August 6, 2026, at 3:00 p.m. Israel time.
- Share Capital Structure: A new proposal (Proposal 4) seeks to amend the Articles of Association to eliminate the par value of the Company's shares, currently NIS 0.01 per share. This is intended to simplify administrative management and provide flexibility.
- Outstanding Shares: As of the record date (July 2, 2026), the Company had 60,809,201,000 Ordinary Shares outstanding, represented by 6,080,920 ADSs.
Guidance, Outlook, and Governance Proposals
The Board of Directors recommends a vote "FOR" all four proposals presented at the meeting:
- Auditor Re-appointment: Re-appoint Kesselman & Kesselman (PwC Israel) as independent auditors for 2026.
- Director Re-election: Re-elect Mr. Rick D. Scruggs and Dr. Shmuel Cabilly to the Board of Directors for a three-year term ending in 2029.
- Executive Engagement: Approve the engagement of Mr. Dror Ben-Asher as Chairman of the Board and Chief Executive Officer for a three-year term commencing August 6, 2026. This proposal requires a "Special Majority" vote under Israeli law.
- Articles Amendment: Eliminate the par value of the Company's shares.
Risks and Contingencies: The filing notes that if a quorum (25% of voting power) is not present within 30 minutes of the scheduled time, the meeting will be adjourned to the next business day. At a reconvened meeting, a single shareholder constitutes a quorum.
Investor Verification Checklist
- Verify the final vote count for Proposal 3 (CEO/Chairman engagement) to ensure the "Special Majority" requirement under Israeli Companies Law was met.
- Confirm the outcome of the proposal to eliminate share par value and its impact on the Company's Articles of Association.
- Review the full financial statements for the fiscal year ended December 31, 2025, which are referenced but not detailed in this filing.
- Check for any shareholder "Position Statements" submitted by July 17, 2026, which may have been filed on a subsequent Form 6-K.